Development Of A Diagnostic Test For Bipolar Disorder (BD)
Funder
National Health and Medical Research Council
Funding Amount
$140,330.00
Summary
A unique test that monitors the rate of switching between the hemispheres of the brain in response to visual stimuli has been devised. A patent application covers an apparatus and test to measure the switching rate between the hemispheres and the way in which such measurements can be used as a means to diagnose bipolar disorder (BD). BD, also called manic depression, is a form of depression that currently affects over six million people worldwide with about three million in the USA alone. The co ....A unique test that monitors the rate of switching between the hemispheres of the brain in response to visual stimuli has been devised. A patent application covers an apparatus and test to measure the switching rate between the hemispheres and the way in which such measurements can be used as a means to diagnose bipolar disorder (BD). BD, also called manic depression, is a form of depression that currently affects over six million people worldwide with about three million in the USA alone. The condition has phases of mania and depression and periods of remittance. Full cycles of BD can occur as many as three times a year and for many patients, this is a lifelong condition. BD is effectively treated, once it is diagnosed. It is estimated that 20% of sufferers go undiagnosed and many more are misdiagnosed. The cost of mis- or non-diagnosis is measured by suicides, the financial burden on society with health care, loss of productivity etc, effects on family and associates, crime, etc. Diagnosis to date is achieved mainly by subjective means such as questionnaires. These instruments do not conclusively separate BD from other forms of depression and schizophrenia, for which treatment is quite different. Nor do they allow for factors such as substance abuse and other medical conditions that the patient may be suffering. BD is hereditary with the slow hemispheric switch rate being an indicator of the genetic trait. This phenomenon allows for an objective test for BD, even if an individual has not had an episode of BD. The slow switch allows relatively easy separation of a BD patient from those exhibiting symptoms that may have other causes.Read moreRead less
The Diagnosis, Biomarker Identification And Measurement Of Drug Efficacy In Mental Illness And Neurological Conditions.
Funder
National Health and Medical Research Council
Funding Amount
$119,050.00
Summary
Globally, 2 billion people suffer from a neuropsychiatric illness. The cost is more than US$2 trillion a year. Hampering early intervention is the current lack of definitive, quantitative techniques for diagnosis and measurement of treatment efficacy. This research will determine whether the disease fingerprints produced by a new technique, EVestG, are diagnostically unique (to schizophrenia, depression and Parkinson's disease) and sensitive to disease progression and treatment response.
Development Of A Multiplex Assay For The Identification Of Women At Risk Of Preterm Labour.
Funder
National Health and Medical Research Council
Funding Amount
$202,350.00
Summary
Preterm birth (ie birth before the 37th week of gestation) is the most significant problem facing contemporary clinical obstetrics in the developed world and occurs in approximately 5% to 12% of all deliveries. Being born too early is the major cause of perinatal morbidity and mortality. Data from Australia indicate that each year, more than 17,000 babies will be born prematurely. Of these infants, over 10,000 will suffer respiratory complications and about 1300 will die during the first 21 days ....Preterm birth (ie birth before the 37th week of gestation) is the most significant problem facing contemporary clinical obstetrics in the developed world and occurs in approximately 5% to 12% of all deliveries. Being born too early is the major cause of perinatal morbidity and mortality. Data from Australia indicate that each year, more than 17,000 babies will be born prematurely. Of these infants, over 10,000 will suffer respiratory complications and about 1300 will die during the first 21 days of life. The sickest and most premature of these infants require admission to a Neonatal Intensive Care Unit in a tertiary hospital. Aside from the medical implications of premature delivery, there is also a considerable fiscal challenge to society. While treatments for the prevention of labour have improved considerably over the past decade, current screening tests of preterm labour (ie Fetal Fibronectin test) are unreliable and have poor positive predictive values. The principal objective of this project is to develop and deliver a multiplex assay for the prediction and diagnosis of human preterm labour. Through the successful application of our own proteomic discovery programmes using both ovine and human cervico-vaginal fluid samples, we have identified several new protein markers of labour. Having completed this Phase 1 biomarker trial and established proof-of-concept, we are now well positioned to initiate a Phase 2 biomarker trial to determine reliable estimates of assay sensitivity and specificity. This project targets the development of a new diagnostic to meet a recognised market gap. Delivery of such a test will create a new market in pregnancy-based clinical diagnostics and significantly impact on improving health care and quality of life for many preterm babies. Should the project be completed as detailed and mitigate some of the risk of commercial development, it would then be realistic to seek substantial funding from the private sector.Read moreRead less